Connect Biopharma Holdings Limited Comprehensive Income
Connect Biopharma Holdings Limited (CNTB) reported Comprehensive Income of -$17.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-12
- Connect Biopharma Holdings Limited comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$17.18M.
- Connect Biopharma Holdings Limited comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$19.27M.
- Connect Biopharma Holdings Limited comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$15.02M.
- Connect Biopharma Holdings Limited comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$17.10M.
- Connect Biopharma Holdings Limited comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$55.01M.
- Connect Biopharma Holdings Limited comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$16.29M.
- Connect Biopharma Holdings Limited comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$62.37M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.18M 10-Q · filed 2026-08-12 | -$36.45M 10-Q · filed 2026-08-12 | -$51.48M derived: sum of 3 quarters · filed 2026-08-12 | -$68.58M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$19.27M 10-Q · filed 2026-05-12 | -$34.29M derived: sum of 2 quarters · filed 2026-05-12 | -$51.40M derived: sum of 3 quarters · filed 2026-05-12 | -$64.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$32.13M derived: sum of 2 quarters · filed 2026-03-31 | -$44.79M derived: sum of 3 quarters · filed 2026-08-12 | -$55.01M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$17.10M 10-Q · filed 2025-11-12 | -$29.77M derived: sum of 2 quarters · filed 2026-08-12 | -$39.98M 10-Q · filed 2025-11-12 | -$49.97M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$12.67M 10-Q · filed 2026-08-12 | -$22.88M 10-Q · filed 2026-08-12 | -$32.87M derived: sum of 3 quarters · filed 2026-08-12 | -$45.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$10.21M 10-Q · filed 2026-05-12 | -$20.20M derived: sum of 2 quarters · filed 2026-05-12 | -$32.51M derived: sum of 3 quarters · filed 2026-05-12 | -$17.58M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$9.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$22.30M derived: sum of 2 quarters · filed 2026-03-31 | -$7.37M derived: sum of 3 quarters · filed 2026-03-31 | -$16.29M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$12.31M 10-Q · filed 2025-11-12 | $2.62M derived: sum of 2 quarters · filed 2025-11-12 | -$6.30M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $14.93M 10-Q · filed 2025-08-13 | $6.01M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$8.92M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$62.37M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |